{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:58:25Z","timestamp":1779209905344,"version":"3.51.4"},"reference-count":129,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["RS-2023-00278980"],"award-info":[{"award-number":["RS-2023-00278980"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:03:34Z","timestamp":1764605014000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology"],"prefix":"10.1053","volume":"62","author":[{"given":"Hayoung","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-4423","authenticated-orcid":false,"given":"Chang-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.005_bib0001","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative strategies for T cell engagers for cancer immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1551424","article-title":"Engaging T cells for cleanup","volume":"16","author":"Mungalov","year":"2025","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0004","doi-asserted-by":"crossref","first-page":"1583044","DOI":"10.3389\/fimmu.2025.1583044","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0005","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428190902943077","article-title":"Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab","volume":"50","author":"Nagorsen","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5891","key":"10.1053\/j.seminhematol.2025.11.005_bib0006","first-page":"974","article-title":"Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science (1979)"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"19-20","key":"10.1053\/j.seminhematol.2025.11.005_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1089\/hum.2021.165","article-title":"Building on synthetic immunology and T cell engineering: a brief journey through the history of chimeric antigen receptors","volume":"32","author":"Abken","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.005_bib0009","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp Mol Med"},{"issue":"670","key":"10.1053\/j.seminhematol.2025.11.005_bib0010","doi-asserted-by":"crossref","first-page":"eabn1082","DOI":"10.1126\/scitranslmed.abn1082","article-title":"CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models","volume":"14","author":"Wei","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1535-7163.MCT-24-0327","article-title":"A B7-H3\u2013Targeted CD28 bispecific antibody enhances the activity of Anti\u2013PD-1 and CD3 T-cell engager immunotherapies","volume":"24","author":"Moore","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"525","key":"10.1053\/j.seminhematol.2025.11.005_bib0012","doi-asserted-by":"crossref","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"issue":"496","key":"10.1053\/j.seminhematol.2025.11.005_bib0013","doi-asserted-by":"crossref","first-page":"eaav5989","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"issue":"3950","key":"10.1053\/j.seminhematol.2025.11.005_bib0015","first-page":"1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science (1979)"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.005_bib0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Pillars article: approaching the asymptote? Evolution and revolution in immunology","volume":"54","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"Volume 12, 1994","key":"10.1053\/j.seminhematol.2025.11.005_bib0018","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended Family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"issue":"5566","key":"10.1053\/j.seminhematol.2025.11.005_bib0019","first-page":"301","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science (1979)"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1073\/pnas.96.1.185","article-title":"A two-step, two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proceed Nat Acad Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0167-5699(92)90198-G","article-title":"The immune system evolved to discriminate infectious nonself from noninfectious self","volume":"13","author":"Janeway","year":"1992","journal-title":"Immunol Today"},{"issue":"4961","key":"10.1053\/j.seminhematol.2025.11.005_bib0022","first-page":"1349","article-title":"A cell culture model for T lymphocyte clonal anergy","volume":"248","author":"Schwartz","year":"1990","journal-title":"Science (1979)"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.11.005_bib0023","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1073\/pnas.90.14.6586","article-title":"Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation","volume":"90","author":"Gimmi","year":"1993","journal-title":"Proceed Nat Acad Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.005_bib0026","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1084\/jem.165.2.302","article-title":"Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo","volume":"165","author":"Jenkins","year":"1987","journal-title":"J Experiment Med"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0027","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0028","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1084\/jem.173.3.721","article-title":"Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation","volume":"173","author":"Linsley","year":"1991","journal-title":"J Experiment Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.11.005_bib0029","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1073\/pnas.88.15.6575","article-title":"B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2","volume":"88","author":"Gimmi","year":"1991","journal-title":"Proceed Nat Acad Sci"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0030","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.147.8.2461","article-title":"CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells","volume":"147","author":"Jenkins","year":"1991","journal-title":"J Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.005_bib0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","article-title":"The B7 and CD28 receptor families","volume":"15","author":"June","year":"1994","journal-title":"Immunol Today"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","article-title":"CD28 costimulation can promote T cell survival by enhancing the expression of bcl-xL","volume":"3","author":"Boise","year":"1995","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0034","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nri1148","article-title":"Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?","volume":"3","author":"Croft","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069677","article-title":"4-1BB Signaling activates the T cell factor 1 effector\/\u03b2-catenin pathway with delayed kinetics via ERK Signaling and delayed PI3K\/AKT activation to promote the proliferation of CD8+ T cells","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","article-title":"Immune regulation by 4-1BB and 4-1BBL: complexities and challenges","volume":"229","author":"Wang","year":"2009","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: a promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.005_bib0040","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.168.10.4897","article-title":"4-1BB Ligand-mediated costimulation of Human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector Function1","volume":"168","author":"Wen","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0041","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.167.3.1313","article-title":"4-1BB Ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar Efficacy1","volume":"167","author":"Cannons","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0042","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0043","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit Rev Immnol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0044","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-018-0659-x","article-title":"Critical role of OX40 in the expansion and survival of CD4 T-cell-derived double-negative T cells","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0045","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.4110\/in.2020.20.e3","article-title":"Co-stimulatory receptors in cancers and their implications for cancer immunotherapy","volume":"20","author":"Jeong","year":"2020","journal-title":"Immune Netw"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.005_bib0046","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692982","article-title":"Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T-cell receptors","volume":"9","author":"Mascarelli","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0048","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0049","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001650","article-title":"4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39(+) CD8 T cells from primary and metastatic sites of epithelial ovarian cancers","volume":"8","author":"Leem","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0052","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ijc.21098","article-title":"Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell\u2013mediated protective immunity in her-2\/neu transgenic mice","volume":"116","author":"Cuadros","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0053","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fimmu.2017.01150","article-title":"Exploring synergy in combinations of tumor-derived vaccines that harbor 4-1BBL, OX40L, and GM-CSF","volume":"8","author":"Manrique-Rinc\u00f3n","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.005_bib0054","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/eji.200838208","article-title":"Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies","volume":"38","author":"Gray","year":"2008","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126765","article-title":"4-1BB Signaling enhances primary and secondary population expansion of CD8+ T cells by maximizing autocrine IL-2\/IL-2 receptor Signaling","volume":"10","author":"Oh","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.005_bib0056","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41551-023-01156-5","article-title":"Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids","volume":"8","author":"Harter","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0057","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.005_bib0058","doi-asserted-by":"crossref","first-page":"121","DOI":"10.36401\/JIPO-24-30","article-title":"4-1BB Antibodies in oncology clinical trials: a review","volume":"8","author":"Schwartz","year":"2025","journal-title":"J Immunother Precis Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.005_bib0059","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the Anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.005_bib0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri3192","article-title":"The storm has cleared: lessons from the CD28 superagonist TGN1412 trial","volume":"12","author":"H\u00fcnig","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0061","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of Urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Can Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0062","article-title":"Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances","volume":"45","author":"Guidi","year":"2025","journal-title":"Am Society Clin Oncol Educat Book"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719116","article-title":"Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models","volume":"12","author":"Warwas","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.005_bib0064","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00262-005-0671-8","article-title":"CD3\u202f\u00d7\u202fCD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation","volume":"54","author":"Willems","year":"2005","journal-title":"Can Immunol Immunother"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.11.005_bib0065","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1073\/pnas.0509404103","article-title":"Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse structure formation in T cells","volume":"103","author":"Doh","year":"2006","journal-title":"Proceed Nat Acad Sci"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943344","article-title":"The immunological synapse: an emerging target for immune evasion by bacterial pathogens","volume":"13","author":"Capitani","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0067","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.005_bib0068","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.MP.0000093627.51090.3F","article-title":"Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases","volume":"16","author":"Tzankov","year":"2003","journal-title":"Modern Pathol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0069","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/blood-2019-129600","article-title":"Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies","volume":"134","author":"Horna","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0070","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0301-472X(99)00072-7","article-title":"Bispecific antibody fragments with CD20\u202f\u00d7\u202fCD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma","volume":"27","author":"Brandl","year":"1999","journal-title":"Exp Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0071","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2024-200666","article-title":"JNJ-87801493 (CD20xCD28), a potential first-in-class CD20 targeted CD28 costimulatory bispecific antibody, enhances the activity of B-cell targeting T-cell engagers in preclinical models","volume":"144","author":"Fontan","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0072","unstructured":"Medicine NLo. A study of JNJ-87801493 in combination with T-cell engagers in participants with B-cell non-hodgkin lymphoid (NHLs) cancer 2025 [accessed 25.07.18. https:\/\/www.clinicaltrials.gov\/study\/NCT06139406."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0073","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2022-159941","article-title":"RG6333 (CD19-CD28), a CD19-targeted affinity-optimized CD28 bispecific antibody, enhances and prolongs the anti-tumor activity of Glofitamab (CD20-TCB) in preclinical models","volume":"140","author":"Sam","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0074","unstructured":"Medicien NLo. A study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of RO7443904 in combination with Glofitamab in participants with relapsed\/refractory B-cell Non-Hodgkin's lymphoma 2024 [accessed 23.08.2024. https:\/\/clinicaltrials.gov\/study\/NCT05219513."},{"issue":"18","key":"10.1053\/j.seminhematol.2025.11.005_bib0075","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0076","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2024-201406","article-title":"CD19-CD28 (RO7443904) Combination with Glofitamab enhances T-cell proliferation and effector function in patients with relapsed\/refractory non-hodgkin lymphoma (R\/R NHL)","volume":"144","author":"Korfi","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0077","unstructured":"Medicine NLo. A trial to study if REGN5837 in combination with Odronextamab is safe for adult participants with aggressive B-cell Non-Hodgkin lymphomas (ATHENA-1) 2025 [accessed 28.08.2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05685173."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0078","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0079","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood-2024-194830","article-title":"A CD38xCD28 costimulatory bispecific antibody demonstrates potent preclinical combinatorial activity with a BCMAxCD3 T cell-engager","volume":"144","author":"Olson","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0080","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood-2024-208776","article-title":"Characterization of Linvoseltamab's BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.005_bib0081","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0082","unstructured":"Medicien NLo. A study to assess the safety and anti-tumor activity of REGN7945 in combination with Linvoseltamab in adult participants with relapsed\/\u200brefractory multiple myeloma (COSTIMM) 2025 [accessed 08.07.2025. https:\/\/clinicaltrials.gov\/study\/NCT06669247."},{"issue":"5_suppl","key":"10.1053\/j.seminhematol.2025.11.005_bib0083","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2025.43.5_suppl.810","article-title":"A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer","volume":"43","author":"Manley","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0084","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03180","article-title":"CD28 expression is required after T cell priming for helper T cell responses and protective immunity to infection","volume":"3","author":"Linterman","year":"2014","journal-title":"Elife"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.005_bib0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2567.2004.01917.x","article-title":"4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine","volume":"112","author":"Munks","year":"2004","journal-title":"Immunology"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0086","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0087","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007364","article-title":"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors","volume":"12","author":"Khushalani","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0088","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2024-200096","article-title":"Englumafusp Alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r\/r B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"issue":"6_Supplement","key":"10.1053\/j.seminhematol.2025.11.005_bib0089","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1538-7445.AM2024-5303","article-title":"Abstract 5303: a novel TIGIT and 4-1BB bispecific antibody, ABL112, exhibits potent in vitro and in vivo antitumor activity through dual immune modulation","volume":"84","author":"Son","year":"2024","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2025.11.005_bib0090","article-title":"573 FS120, an OX40\/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies","volume":"9","author":"Lakins","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.11.005_bib0091","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.vaccine.2004.10.031","article-title":"T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine","volume":"23","author":"Haas","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0092","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1073\/pnas.1315606111","article-title":"CD28 and CD3 have complementary roles in T-cell traction forces","volume":"111","author":"Bashour","year":"2014","journal-title":"Proceed Nat Acad Sci"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0093","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 Agonists and Combination Immunotherapy: putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.005_bib0094","doi-asserted-by":"crossref","first-page":"160","DOI":"10.61091\/jpms202413223","article-title":"Expressions of CD80 and CD86 in cancer patients and its prognostic significance","volume":"13","author":"Ismael","year":"2024","journal-title":"J Pioneer Med Sci"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.005_bib0095","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2022.04.004","article-title":"Mechanisms of T cell exhaustion guiding next-generation immunotherapy","volume":"8","author":"Zebley","year":"2022","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.005_bib0096","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.11.005_bib0097","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"issue":"86","key":"10.1053\/j.seminhematol.2025.11.005_bib0098","doi-asserted-by":"crossref","first-page":"eadg0878","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+PD-1+CD8 T cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci Immunol"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.11.005_bib0099","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138729","article-title":"CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation","volume":"5","author":"Beckermann","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.005_bib0100","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2007-08-110072","article-title":"Bispecific anti-CD20\/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action","volume":"111","author":"Qu","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.005_bib0101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 Co-engagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.005_bib0102","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0104","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0105","article-title":"Exploring T-cell bispecific antibodies in gynecologic malignancy","volume":"59","author":"O\u2019Brien","year":"2025","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.005_bib0106","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.11.005_bib0107","first-page":"79","article-title":"A Case Report of sustained cytokine release syndrome due to Glofitamab and literature review","volume":"29","author":"Yang","year":"2025","journal-title":"Clin Pharmacol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.005_bib0108","doi-asserted-by":"crossref","first-page":"9493","DOI":"10.1182\/blood-2022-159561","article-title":"Risk of Cytokine release syndrome with glofitamab is predicted by an updated model with a potential clinical application","volume":"140","author":"Komanduri","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.11.005_bib0109","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14712598.2022.2098674","article-title":"Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0111","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.005_bib0112","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"Immunother Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0113","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell Therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.005_bib0115","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0116","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0117","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4062\/biomolther.2024.146","article-title":"Mechanism of action and pharmacokinetics of approved bispecific antibodies","volume":"32","author":"Choi","year":"2024","journal-title":"Biomol Ther"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0118","first-page":"2021","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.005_bib0119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0120","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.005_bib0121","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.005_bib0122","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.005_bib0123","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384467","article-title":"Modular design of bi- and multi-specific knob domain fusions","volume":"15","author":"Kuravsky","year":"2024","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.005_bib0125","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.005_bib0126","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.005_bib0127","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41435-020-00118-0","article-title":"Genomic profiling of T-cell activation suggests increased sensitivity of memory T cells to CD28 costimulation","volume":"21","author":"Glinos","year":"2020","journal-title":"Genes & Immunity"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.005_bib0128","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/sj.emboj.7601146","article-title":"T-cell tolerance or function is determined by combinatorial costimulatory signals","volume":"25","author":"Nurieva","year":"2006","journal-title":"EMBO J"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.11.005_bib0129","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells14141077","article-title":"Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma","volume":"14","author":"Tedder","year":"2025","journal-title":"Cells"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632500054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632500054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:54:21Z","timestamp":1777442061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632500054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S003719632500054X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}